This company listing is no longer active
Karo Pharma Balance Sheet Health
Financial Health criteria checks 1/6
Key information
104.8%
Debt to equity ratio
SEK 8.65b
Debt
| Interest coverage ratio | 0.2x |
| Cash | SEK 353.10m |
| Equity | SEK 8.26b |
| Total liabilities | SEK 10.24b |
| Total assets | SEK 18.49b |
Recent financial health updates
Karo Pharma (STO:KARO) Has No Shortage Of Debt
Oct 14
Is Karo Pharma (STO:KARO) A Risky Investment?
Jul 10Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt
Mar 23Recent updates
Karo Pharma (STO:KARO) Has No Shortage Of Debt
Oct 14Is Karo Pharma (STO:KARO) A Risky Investment?
Jul 10Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt
Mar 23Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality
Feb 24Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?
Feb 22Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?
Feb 01
Financial Position Analysis
Short Term Liabilities: KARO's short term assets (SEK1.7B) exceed its short term liabilities (SEK626.0M).
Long Term Liabilities: KARO's short term assets (SEK1.7B) do not cover its long term liabilities (SEK9.6B).
Debt to Equity History and Analysis
Debt Level: KARO's net debt to equity ratio (100.5%) is considered high.
Reducing Debt: KARO's debt to equity ratio has increased from 59.5% to 104.8% over the past 5 years.
Debt Coverage: KARO's debt is not well covered by operating cash flow (5.9%).
Interest Coverage: KARO's interest payments on its debt are not well covered by EBIT (0.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/25 08:12 |
| End of Day Share Price | 2022/11/24 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Karo Pharma AB (publ) is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Lindström | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mats Liss | Kepler Cheuvreux |